Trial · NCT03923933

Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial

NCT03923933, Phase 2, Completed, Hospital General de México Dr. Eduardo Liceaga; results first posted 2020-03-10

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial. Trials, record NCT03923933. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03923933

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial
NCT number: NCT03923933
Status: Completed
Phases: Phase 2
Enrollment: 34 participants, actual
Lead sponsor: Hospital General de México Dr. Eduardo Liceaga
Conditions: Renal Insufficiency, Chronic
Interventions: Chlorthalidone, Bumetanide
First posted: 2019-04-23
Last updated: 2020-11-23
Results first posted: 2020-03-10

Source ClinicalTrials.gov

Registered outcomes7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Total Body Water	Change from Basal to day 28	Measured by bioelectrical impedance analysis, compared to the initial measurement
Secondary	Change in Mean Arterial Pressure	Change from Basal to day 28	decrease in blood pressure compared wit baseline measure (mmhg)
Secondary	Change in the Fractional Excretion of Sodium	Change from Basal to day 28	Increase in the fractional excretion of sodium compared with the baseline measure
Secondary	Change in Extracellular Water	Change from Basal to day 28	Decrease in extracellular water measured by bioelectrical impedance analysis
Secondary	Change in Extracellular Water / Total Body Water Ratio	Change from Basal to day 28	Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis
Secondary	Change in Systolic Blood Pressure	Change from Basal to day 28
Secondary	Change in Diastolic Blood Pressure	Change from Basal to day 28

Source ClinicalTrials.gov

Outcomes7

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change in Total Body Water	Change from Basal to day 28	litres	MEAN
SECONDARY	Change in Mean Arterial Pressure	Change from Basal to day 28	mmHg	MEAN
SECONDARY	Change in the Fractional Excretion of Sodium	Change from Basal to day 28	percentage of sodium excreted	MEAN
SECONDARY	Change in Extracellular Water	Change from Basal to day 28	litres	MEAN
SECONDARY	Change in Extracellular Water / Total Body Water Ratio	Change from Basal to day 28	percentage of ECW/TBW	MEAN
SECONDARY	Change in Systolic Blood Pressure	Change from Basal to day 28	mmHg	MEAN
SECONDARY	Change in Diastolic Blood Pressure	Change from Basal to day 28	mmHg	MEAN

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Total Body Water	Placebo	-0.075	Standard Deviation 1.78	litres
Change in Total Body Water	Treatment Grup	-4.36	Standard Deviation 3.29	litres
Change in Mean Arterial Pressure	Placebo	-5.4	Standard Deviation 14.3	mmHg
Change in Mean Arterial Pressure	Treatment Grup	-18.1	Standard Deviation 8.7	mmHg
Change in the Fractional Excretion of Sodium	Placebo	-0.348	Standard Deviation 3.48	percentage of sodium excreted
Change in the Fractional Excretion of Sodium	Treatment Grup	0.598	Standard Deviation 2.29	percentage of sodium excreted
Change in Extracellular Water	Placebo	-0.15	Standard Deviation 1.2	litres
Change in Extracellular Water	Treatment Grup	2.55	Standard Deviation 1.1	litres
Change in Extracellular Water / Total Body Water Ratio	Placebo	-0.24	Standard Deviation 1.42	percentage of ECW/TBW
Change in Extracellular Water / Total Body Water Ratio	Treatment Grup	-2.92	Standard Deviation 4.76	percentage of ECW/TBW

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	17
Overall Study	STARTED	Treatment Grup	17
Overall Study	COMPLETED	Placebo	16
Overall Study	COMPLETED	Treatment Grup	16
Overall Study	NOT COMPLETED	Placebo	1
Overall Study	NOT COMPLETED	Treatment Grup	1

Source ClinicalTrials.gov

Adverse events10

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Creatinine Increase	Renal and urinary disorders	Placebo	4	16	4
other	Creatinine Increase	Renal and urinary disorders	Treatment Grup	11	16	11
other	Hyponatremia	Renal and urinary disorders	Placebo	1	16	1
other	Hyponatremia	Renal and urinary disorders	Treatment Grup	2	16	2
other	hypokalemia	Renal and urinary disorders	Placebo	0	16	0
other	hypokalemia	Renal and urinary disorders	Treatment Grup	2	16	2
other	hyperuricemia	Renal and urinary disorders	Placebo	4	16	4
other	hyperuricemia	Renal and urinary disorders	Treatment Grup	4	16	4
serious	Major adverse cardiovascular events	Cardiac disorders	Placebo	0	16	0
serious	Major adverse cardiovascular events	Cardiac disorders	Treatment Grup	1	16	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	0	16
Total, all-cause mortality	Treatment Grup	0	16
Total, other adverse events	Placebo	4	16
Total, other adverse events	Treatment Grup	11	16
Total, serious adverse events	Placebo	0	16
Total, serious adverse events	Treatment Grup	1	16

Source ClinicalTrials.gov

Papers50

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
4579972	BACKGROUND	PubMed
4838012	BACKGROUND	PubMed
4847130	BACKGROUND	PubMed
5082545	BACKGROUND	PubMed
7046434	BACKGROUND	PubMed
7967362	BACKGROUND	PubMed
8583780	BACKGROUND	PubMed
10207256	BACKGROUND	PubMed
11856788	BACKGROUND	PubMed
11904577	BACKGROUND	PubMed

1 to 10 of 50

See all 50 papers

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Treatment Grup vs Placebo: deaths from any cause	Trial comparisons
Treatment Grup vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03923933

GET https://conductscience.org/api/trials/v1/NCT03923933/papers?page=2

API reference For AI assistants